Moderna Stock Doubles Year-to-Date, But Wall Street Remains Largely on the Sidelines

Moderna (MRNA) shares have more than doubled in value this year, but a deep divide on Wall Street suggests the rally may have outpaced the company's fundamental progress. The stock has surged +101.7% year-to-date to trade at $60.28, yet the overwhelming analyst consensus remains cautious.

Analyst Skepticism Persists

Despite the stock's strong performance, the majority of analysts covering Moderna are hesitant to recommend buying the shares. The current consensus breakdown shows 17 'Hold' ratings, compared to just three 'Buys' and three 'Sells', according to data from Investing.com.

Several firms have recently raised their price targets but stopped short of upgrading their ratings. Goldman Sachs increased its target to $67 from $49 but maintained a 'Neutral' rating. Similarly, Piper Sandler lifted its target to $77 while keeping an 'Overweight' rating. Analysts at Wolfe Research, who hold a $25 target, noted that while corporate updates have driven the rally, "the fundamental story remains the same" pending hard data.

Pipeline Hopes vs. Financial Headwinds

The bull case for Moderna is centered on the potential of its mRNA pipeline beyond COVID-19, particularly in oncology. The company recently dosed the first patient in a Phase 1 trial for mRNA-4200, a cancer therapy developed with Immatics. However, investors are facing a significant cash burn, with consensus estimates projecting per-share losses of $7.95 in 2026 and $6.25 in 2027.

Ad

Key developments investors are watching include:

• Melanoma Vaccine: Interim Phase 3 data for its personalized cancer vaccine, mRNA-4157, is expected in late 2026. This is widely seen as the single most important binary event for the company's future.
• Combination Vaccine: Potential regulatory approvals for a combination flu and COVID-19 vaccine could open a new revenue stream in 2027.
• Financials: The company reported a negative gross margin of 70% on revenue of $2.23 billion over the last twelve months and recently paid $178 million to settle a patent lawsuit.

Outlook Hinges on Clinical Data

With the stock having already doubled, Wall Street's message is that much of the near-term optimism is now priced in. The stock currently trades above InvestingPro's Fair Value estimate of $55.06 and near several newly raised analyst targets.

The ultimate trajectory for Moderna's stock now hinges on the late 2026 data for its melanoma vaccine. A positive result could validate its entire mRNA oncology platform and justify a higher valuation, while a failure could erase a significant portion of this year's gains.